30 closest matches · ranked by relevance
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Lung Cancer
Primary: Overall Survival at 2 Years — 36.60 percentage of participants
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Extensive Stage Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Small Cell Lung Cancer
Primary: Part A: Percentage of Participants Achieving an Overall Response (Overall Response Rate) — 2.6 percentage of participants
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Carcinoma, Small Cell · Small Cell Lung Cancer
Primary: Objective Response Rate — 3 Participants
Lung Cancer
Primary: The Objective Overall Response — 7; 12; 7; 19 participants
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I) — 25 mg/day
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response Rates (Complete and Partial) Evaluated Using RECIST Criteria — 2 participants
Extensive Stage Small Cell Lung Cancer
Primary: Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST) — 0.697; 0.576 proportion of participants
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Lung Cancer
Primary: Confirmation of Tumor Targeting as Measured by the Number of Patients With Assessable Lesions Greater Than or Equal to 2 cm Measured by FDG-PET and SPECT Imaging. — 5; 5…
Small Cell Lung Cancer
Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Lung Cancer
Primary: Time to Progression — 123 days
Lung Cancer
Primary: Overall Survival — 9.9; 9.1 Months
Extensive Stage Small Cell Lung Carcinoma · Limited Stage Small Cell Lung Carcinoma
Primary: Number of Participants With Deterioration in HVLT-R Delayed Recall Score at Six Months (Phase III) — 33; 27 Participants — p=0.28
Small Cell Lung Cancer
Primary: Time to Disease Progression - Median Time to Progression and Log-Rank Test — 5.68; 5.62 Months — p=0.10
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Small Cell Lung Cancer
Primary: Determine the Proportion of Previously Treated Small Cell Lung Cancer (SCLC) Patients Whose Disease Has Not Progressed Following 6-weeks (2 Cycles) of Treatment With…
Small-cell Lung Cancer
Primary: Overall Survival (OS) — 8.6; 7.6 months — p=0.9029
Limited Stage Small Cell Lung Cancer
Primary: Overall Survival — 21 months
Lung Cancer · Cancer of Lung · Pulmonary Cancer
Primary: Response Rate (RR) — 0; 0; 2; 15 Participants
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg